论文部分内容阅读
目的:研究沐舒坦雾化吸入治疗法对老年慢性支气管炎急性发作的临床疗效。方法:将我院在2015年4月-2016年4月所接受的102例急性发作慢性支气管炎老年患者纳入此次研究中,根据治疗方法不同分成实验组和对照组,每组51例;对照组进行传统对症治疗,而实验组则实施沐舒坦的雾化吸入法。对比两组患者临床医学疗效。结果:据两组患者采纳治疗手段不同,会发现实验组医学整体疗效为98.04%,而对照组达70.59%,根据数据足以看出实验组优于对照组,且差异明显,具有统计学意义(P<0.05)。结论:针对于慢性支气管炎急性发作高龄患者而言,采用沐舒坦雾化吸入治疗更为适宜,不仅效果确切,还可明显对患者临床症状起到改善的作用,从而减轻患者痛苦,因此值得临床进一步推广。
Objective: To study the clinical efficacy of mucosolvan inhalation therapy in the treatment of acute exacerbation of senile chronic bronchitis. Methods: A total of 102 elderly patients with acute exacerbation of chronic bronchitis admitted in our hospital from April 2015 to April 2016 were enrolled in this study. According to the different treatment methods, the patients were divided into experimental group and control group, with 51 cases in each group. Group for the traditional symptomatic treatment, while the experimental group is the implementation of mucosolvan inhalation. Comparison of two groups of patients clinical efficacy. Results: According to the different treatment methods adopted by the two groups, the overall curative effect of the experimental group was 98.04%, while that of the control group was 70.59%. According to the data, the experimental group was better than the control group, and the difference was statistically significant P <0.05). Conclusion: In view of the elderly patients with acute exacerbation of chronic bronchitis, inhalation of mucosolvan is more appropriate, not only the exact effect, but also significantly improve the clinical symptoms of patients to reduce the suffering of patients, so it is worth clinical Further promotion.